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Key Points
• Urinary 3-IS levels predict
outcome after ASCT and are
associated with antibiotics
and NOD2/CARD15 variants.
Indole, which is produced from L-tryptophan by commensal bacteria expressing tryptopha-
nase, not only is an important intercellular signal in microbial communities, but also
modulates mucosal barrier function and expression of pro- and anti-inflammatory genes
by intestinal epithelial cells. Here, we hypothesized that decreased urinary excretion of
3-indoxyl sulfate (3-IS), the major conjugate of indole found in humans, may be a marker
of gut microbiota disruption and increased risk of developing gastrointestinal (GI) graft-
versus-host-disease. Using liquid chromatography/tandem mass spectrometry, 3-IS was
determined in urine specimens collectedweeklywithin the first 28 days after allogeneic stemcell transplantation (ASCT) in 131 patients.
Low 3-IS levels within the first 10 days after ASCT were associated with significantly higher transplant-related mortality (P5 .017) and
worse overall survival (P 5 .05) 1 year after ASCT. Least absolute shrinkage and selection operator regression models trained on log-
normalizedcountsof763operational taxonomicunitsderived fromnext-generationsequencingof thehypervariableV3regionof the16S
ribosomal RNA gene showed members of the families of Lachnospiraceae and Ruminococcaceae of the class of Clostridia to be
associatedwithhighurinary 3-IS levels,whereasmembersof theclassofBacilliwereassociatedwith low3-IS levels.Risk factorsof early
suppressionof3-IS levelswere the typeofGIdecontamination(P5 .01),earlyonsetofantibiotic treatment (P5 .001),andrecipientNOD2/
CARD15 genotype (P5 .04). In conclusion, our findings underscore the relevance ofmicrobiota-derived indole andmetabolites thereof
in mucosal integrity and protection from inflammation. (Blood. 2015;126(14):1723-1728)
Introduction
Allogeneic stem cell transplantation (ASCT) constitutes a potential
curative therapy for various hematologic malignancies, bone marrow
failure, and immune deﬁciency syndromes. However, this treatment
is still associated with a high risk of mortality because of infectious
complications and acute graft-versus-host disease (GVHD). A signif-
icant part of these severe complications originates from the gastroin-
testinal (GI) tract.1
The introduction of 16S ribosomal RNA (rRNA) sequencing has
provided novel insights into the diversity and complexity of the gut
ecosystem.2 Loss of a diverse composition of the microbiome has been
associated with a variety of diseases including inﬂammatory bowel
and autoimmune diseases. At least in part this may be because of the
increasingly recognized role that commensal bacteria play in main-
taining immunologic homeostasis and epithelial integrity and in
exerting anti-inﬂammatory effects and intestinal tolerance by inducing
regulatory T cells.3,4
Recent studies have demonstrated an association between intestinal
bacterial diversity in both mouse models and humans and outcome of
ASCT.5-7A signiﬁcantly higher transplant -relatedmortality (TRM)was
observed in patients with low intestinal microbiome diversity, whereas
patients with a microbiome dominated by commensal bacteria showed
a better overall survival (OS) within 3 years after transplantation.8
Recently, we observed urinary levels of 3-indoxyl sulfate (3-IS),
which originates from the degradation of tryptophan to indole by in-
testinal microbiota followed by microsomal oxidation to indoxyl and
sulfonation in the liver, to be associated with gut microbiota disruption
in patients undergoing ASCT.6 We investigated whether urinary 3-IS
levels at the timeofASCTand early thereafter can serve as predictors of
outcome as measured by TRM and OS. Our ﬁndings not only reveal
a prognostic impact of urinary 3-IS levels, but also indicate a direct
associationof 3-IS levelswith the presenceofmembers of theFirmicute
families Lachnospiraceae and Ruminococcaceae in the gut microbiota.
Patients, materials, and methods
Patients
A total of 131 adult patients undergoing ASCT between September 2008 and
February 2014 at the UniversityMedical Center of Regensburg were enrolled in
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this prospective single-center study.Weexpandedour previous pilot cohort of 51
patients with an additional cohort of 80 consecutive patients undergoing ASCT
between April 2012 and February 2014.9 The study had been approved by the
EthicsCommittee of theUniversityMedicalCenter ofRegensburg.Afterwritten
informed consent, stool and urinary specimens were collected at a minimum of
6different timepoints startingprior to admissionuntil day28afterASCT:prior to
admission, day of transplantation (day22 to12), at least once between days12
and110, andapproximatelyday114 (days111 to117), day121 (days118 to
124), and day128 (days125 to130), respectively. All specimens were stored
at280°C until analysis.
Mean age of the patients was 50.8 (6 12.1) years. Underlying diseases were
acute leukemia (n 5 72), lymphatic neoplasia (n 5 25), myelodysplastic
syndrome (n 5 17), chronic myelogenous leukemia (n 5 14), and aplastic
anemia (n5 3). Thirty-seven patients received grafts from HLA-identical
siblings, and 94 patients received grafts from matched unrelated donors.
Nineteen and 112 patients, respectively, were treated with full and reduced
intensity conditioning. All patients received prophylactic antibiotics from
start of conditioning until engraftment. Originally, patients (n5 57) received
ciproﬂoxacin and metronidazole. Starting in April 2012, patients (n5 74) were
treated instead with rifaximin, a topical rifamycin derivative with low GI re-
sorption, to prevent the emergence of vancomycin-resistant enterococci. In case
of neutropenic infectious complications, piperacillin/tazobactam was used for
empiric ﬁrst-line therapy followed by meropenem and vancomycin as second-
line therapy. Overall, 117 out of 131 patients (89.3%) required antibiotic treat-
ment during neutropenia.
Analysis of urinary 3-IS
Analysis of 3-IS was performed by reversed-phase liquid chromatography–
electrospray ionization–tandem mass spectrometry in negative ion multiple
reaction monitoring mode using method parameters recently described.10 In
contrast to the original method, quantiﬁcation was performed with 3-IS-d4
(TorontoResearchChemicals, Toronto,ON,Canada) instead of isatin as internal
standard. The transitionm/z 216.0 (Q1) to m/z 80.0 (Q3) was monitored for the
deuterated3-IS. For sample preparation, 10mLofurinewasmixedwith 10mLof
internal standard (10 mM 3-IS-d4 in water) and diluted with water (PURELAB
Plus water) to a ﬁnal volume of 100 mL. Gradient elution with mobile phase A
(0.1% formic acid in water, volume to volume ratio) and mobile phase B (0.1%
formic acid in acetonitrile, volume to volume ratio) began with a 1-minute linear
increase from 0% to 50% B, hold at 50% B for 4 minutes, 5 to 6 minutes from
50% to 100% B, hold at 100% B for 1 minute, return to 0% B at 7.1 minutes,
and equilibration for 3.9 minutes.11 The lower limit of quantitation (LLOQ) was
4nmol/L.Valuesbelow theLLOQwere substitutedwithLLOQ/2 for subsequent
statistical analyses.Theupper limitofquantitationwas30mmol/L.All specimens
that had yielded initially concentrations above the upper limit of quantitation
were diluted and reanalyzed. Finally, obtained concentration values were
corrected to urinary creatinine (crea) as described previously.6
Genotyping of NOD2/CARD15
To assess a potential association between NOD2/CARD15 polymorphism and
urinary 3-IS levels, genomic DNA from the 131 study participants and their
corresponding donors was prepared from peripheral blood cells (EDTA blood)
prior to admission for ASCT. TaqMan polymerase chain reaction (PCR) for
single-nucleotide polymorphisms8, 12, and13 for theNOD2/CARD15genewas
performed as previously described.11 Because the study group included only
a single case each of compound heterozygous or homozygous mutation, the
NOD2/CARD15 “risk allele” was deﬁned as any mutation in single-nucleotide
polymorphisms 8, 12, or 13.
Bioinformatics and data analysis
To assess microbial species associated with 3-IS levels, we reanalyzed the
hypervariable V3 region 16S rRNA gene sequences that had been previously
generated on a Roche Diagnostics 454 GS FLX sequencer employing GS FLX
titanium chemistry,6 using theQIIMEpipeline.12 Readswere qualityﬁltered and
trimmed with default settings. The remaining sequences were combined into
operational taxonomic units (OTUs) by using the Quantitative Insights Into
Microbial Ecology (QIIME) script pick_closed_reference_otus.py against the
SILVA ribosomal RNA gene database (release 111, available at http://www.arb-
silva.de/download/archive/qiime/) at 97% sequence identity.13 Taxonomy was
assigned as provided by SILVA DB.
Based on the resulting read count data, the Simpson index of diversity was
calculated for quantiﬁcation of bacterial intestinal diversity and correlated with
matching urinary levels of 3-IS using the Pearson correlation coefﬁcient. The
microbiome signature to predict urinary 3-IS levels was computed using least
absolute shrinkage and selection operator (LASSO) regressionmodels trained on
the proﬁle of log-normalized counts of 763OTUswith.60 counts across the 70
stool specimens, for which also urinary 3-IS levels were available, as predictors.
All predictor variableswere scaled to standardunits to allow for a fair comparison
of regression coefﬁcients across predictors. Cross-validated predictions were
compared with observed urinary log (3-IS/mmol crea) levels. The sparseness of
the model was calibrated for every cross-validation run separately in a nested
cross-validation loop. Finally, a singlemodel was trained on the full data set, and
predictorswith nonzero regression coefﬁcientswere reported as signatureOTUs.
Computations were done in R using the glmnet package.14
Normally and nonnormally distributed continuous data are presented as
mean (standard deviation) or median (range), respectively. Accordingly, ei-
ther a 2-sided t test or the Mann-Whitney U test was used to perform group
comparisons. Absolute and relative frequencies were given for categorical
data and compared between study groups by x2 tests. Multivariate logistic
regression including gut decontamination, use of systemic antibiotics, and
NOD2/CARD15mutation was performed to search for factors inﬂuencing
urinary 3-IS concentrations. Kaplan-Meier analysis was performed to assess
survival and nonrelapsemortality, andCox regressionwas used formultivariate
Figure 1. One-year TRM in relation to median 3-IS level within the first 10 days
after ASCT. (A) One-year TRM in patients with low 3-IS levels (#6.9 mmol/mmol
crea, n 5 75) between days 0 and 10 after ASCT was significantly increased (P5 .017)
as compared with patients with high 3-IS levels (n 5 55). (B) One-year OS in patients
with low levels (#6.9 mmol/mmol crea, n 5 75) of 3-IS between days 0 and 10 after
ASCT was significantly decreased (P 5 .05) as compared with patients with high 3-IS
levels (n 5 55).
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assessment of risk factors. IBM SPSS Statistics 22 (SPSS Inc., Chicago, IL)
was used for these analyses.
Results
Low urinary 3-IS levels are associated with poor outcome
after ASCT
Patients with TRM within the ﬁrst 12 months after ASCT (N 5 22)
showed lower urinary 3-IS levels within the ﬁrst 10 days after ASCT
with amedian of 1.3 (0.0-29.6)mmol/mmol crea as comparedwith all
other patients (N 5 109) with 8.4 (0.0-101.9) mmol/mmol crea
(P5 .010). In contrast, 3-IS levels prior toASCTand at later time points
did not differ signiﬁcantly between patients with and without TRM.
Patients were next classiﬁed into either low or high 3-IS based on
3-IS concentrations between day 0 and day 10 after ASCT. In case of
several available 3-ISmeasurements within this period, we chose the
mean of all 3-IS values obtained between day 0 and 10 after ASCT.
Kaplan-Meier estimates for TRM and OS for each group are shown
in Figure 1. Patients with low urinary 3-IS levels (#6.9 mmol/mmol
crea) displayed a signiﬁcantly higher TRM in the ﬁrst 12 months
after ASCT than patients with high (.6.9 mmol/mmol crea) urinary
3-IS concentrations (P5 .017; Figure 1A). GI GVHD-related com-
plications were the primary cause of TRM in 19 of 22 (86.4%)
patients (P , .001). The remaining 3 patients died of Epstein-Barr
virus–associated posttransplant lymphoproliferative disorder, fun-
gal septicemia, and hepatorenal syndrome, respectively. Similarly,
OS within the ﬁrst year after ASCT was reduced in the low-3-IS
group (P5 .05; Figure 1B). Relapse-related mortality did not differ
between the low- and high-3-IS groups (not signiﬁcant). The neg-
ative effect of low 3-IS levels on TRMpersisted until the most recent
follow-up in January 2015 (P 5 .02; supplemental Figure 1; avail-
able on the BloodWeb site), and the effect on OSwas not any longer
signiﬁcant (P 5 .07; supplemental Figure 2).
Table 1 shows the results of theCoxproportional hazards analysis
for TRM. Low urinary 3-IS levels between day 0 and 10 after ASCT
were signiﬁcantly associated with increased risk of TRM (P5 .013),
whereas classical risk factors such as age, stage, donor type, condi-
tioning,median duration of systemic antibiotic therapy, and duration
of neutropenia were not. The same held for NOD2/CARD15 poly-
morphism (data not shown).
3-IS levels can be predicted from the gut
microbiota composition
We next asked whether it is possible to predict urinary log 3-IS
concentrations if oneknows themicrobiomecompositionof amatching
Table 1. Multivariate risk factor analysis for TRM in the first 12 mo
after ASCT
Risk factor P HR 95% CI for HR
Low 3-IS level days 0 to 10 (n 5 75) .013 3.895 1.329-11.412
Patient’s age (.50 y, n 5 81) .078 2.499 0.903-6.916
Donor (MUD, n 5 94) .861 1.096 0.394-3.046
Stage of underlying disease
(advanced, n 5 45)
.623 1.250 0.514-3.040
Conditioning (RIC, n 5 112) .943 0.973 0.464-2.041
Length of neutropenia (median 21 d,
range 0-40 d)
.636 1.316 0.422-4.103
Duration of antibiotic therapy (median 19 d,
range 0-40 d)
.351 0.627 0.234-1.674
Low urinary 3-IS levels between days 0 and 10 after ASCT were significantly
associated with increased risk of TRM (n 5 130). In the table, numbers for high-risk
groups are indicated for categorical variables. Significance level ,.05.
CI, confidence interval; HR, hazard ratio; MUD, matched unrelated donor; RIC,
reduced intensity conditioning.
Figure 2. Microbiome composition is associated with urinary 3-IS levels. (A) LASSO regression was used to predict 3-IS levels from microbiome compositions in cross-
validation. Shown is a scatter plot of predicted vs observed urinary 3-IS/mmol crea concentrations. Both axes are plotted on a logarithmic scale. The Pearson correlation coefficient
r is 0.703 (P , .001). (B) Heat map representation of the relative abundance of the 18 predictive OTUs in n 5 70 stool specimens. The abundance increases from blue to yellow.
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stool specimen. To fully exploit the proﬁles, we used LASSO
regression models trained on the proﬁle of log-normalized counts of
the 763OTUswith.60 counts across stool specimens as predictors for
log(3-IS/mmol crea) levels and compared cross-validated predictions
with observed urinary log(3-IS/mmol crea) levels in Figure 2A. The
predicted and observed log(3-IS) levels show a Pearson correlation
coefﬁcient of r 5 0.703 (P , .001). These associations suggests that
knowing the intestinal microbiome composition may allow prediction
of urinary 3-IS levels. The OTUs with nonzero regression coefﬁcients
of a model trained on 70 stool specimens are summarized in supple-
mental Table 1 (the respective FASTA ﬁles can be found in supple-
mental Table 2). The LASSO model combines standardized counts of
a total of 18 OTUs to a weighted average that is predictive of 3-IS
concentrations. Compared with the correlation between the Simpson
index of diversity and urinary 3-IS levels (r 5 0.252, P 5 .035),
thismicrobiomesignature indexcorrelatesmore stronglywithobserved
3-IS concentrations. Hence, not only the diversity of the microbiome
but its speciﬁc composition is indicative of urinary 3-IS. Interestingly,
themajority ofOTUs associatedwith high urinary 3-IS levels belong to
the families of Lachnospiraceae, a prominent member of which is
Eubacterium rectale, and Ruminococcaceae, both of which belong to
the class of Clostridia (Figure 2B). In contrast, low urinary 3-IS levels
were primarily associated with members of the class of Bacilli, in
particular members of the order of Lactobacillales. It is important to
note that inclusion in the model does not necessarily mean that these
OTUs are either capable or incapable of converting tryptophan to
indole. The model may also include OTUs that do not produce indole
themselves but grow either better or worse in the presence of indole.
Factors associated with low urinary levels of 3-IS: antibacterial
prophylaxis, early treatment with broad-spectrum antibiotics,
and NOD2/CARD15 genotype
Searching for factors that may be associated with 3-IS, we found sig-
nificantly lower 3-IS concentrations in patients receiving ciproﬂoxacin/
metronidazole (N 5 56) compared with patients receiving rifaximin
(N 5 74) for gut decontamination (Table 2). A similar effect was
observed for the prolonged or early use of systemic antibiotics. In
patients with low urinary 3-IS levels, systemic antibiotic treatment had
been started more frequently prior to ASCT as compared with patients
with high 3-IS levels (Figure 3). There was no difference in 3-IS levels
with respect to intensity of conditioning, stage of underlying disease, or
patient’s age. In addition, NOD2/CARD15 risk alleles affected 3-IS
levels (Table 2). In multivariate data analysis, type of gut de-
contamination, early treatment of broad-spectrum antibiotics prior to
ASCT, and presence of a NOD2/CARD15 risk allele in ASCT
recipientswere independent risk factors for low levels of 3-ISwithin the
ﬁrst 10 days after ASCT (Table 3). The mean urinary 3-IS level in
ASCT recipients carrying any of the 3 NOD2/CARD15 risk alleles
tested were 2.8 mmol/mmol crea (range 0-9.7). If both donor and
recipient carried a risk allele, the mean was 3.2mmol/mmol crea (range
0-12.4). In contrast, if only the donor carried a risk allele, themeanurinary
3-IS levelwas 12.5mmol/mmol crea (range 0-63.6), whichwas similar to
the mean level of 12.7 mmol/mmol crea (range 0-101.9) observed
when both donor and recipient carried the wild-type allele only.
After day 10, the difference in mean urinary 3-IS concentration
disappeared between ASCT recipients carrying a risk allele
(0.1 mmol/mmol crea; range 0.0-29.9) and those homozygous for
the wild-type allele (0.1 mmol/mmol crea; range 0.0-59.5).
Discussion
In this prospective study,we report that lowurinary 3-IS levels between
days 0 and 10 after ASCT are associated with poor early and long-term
outcome because of an increased frequency of lethal complications
mostly as a consequence of GI GVHD. Further, a LASSO regression
model trained on the proﬁle of log-normalized counts of 763OTUs that
were derived from next-generation sequencing of the hypervariable V3
region of the 16S rRNA gene identiﬁed an 18-OTU signature that
predicts 3-IS levels in cross-validation. Among the signature OTUs,
members of the Lachnospiraceae andRuminococcaceae, which belong
to the order of Clostridiales, are found in cases with high urinary 3-IS
levels, whereasmembers of the orders of Lactobacillales andBacillales
were found in cases with low levels. Interestingly, among the OTUs
associated with low urinary 3-IS levels was AY033814 (supplemental
Table 1), which represents a cluster of hypervariable V3 16S rRNA
sequence reads with 97% similarity, including among others the en-
terococcal strainsEnterococcus faecium andEnterococcus gilvus. This
is in line with our previous study, in which we observed E. faecium
signiﬁcantly more frequently posttransplant, especially in patients with
subsequent or active GI GVHD.6
Figure 3. Suppression of 3-IS in relation to start of antibiotic treatment in 117
patients requiring antibiotic treatment. Systemic antibiotic therapy before ASCT
was more frequently observed in patients with 3-IS levels below the median.
Table 2. Analysis of factors influencing urinary 3-IS concentrations
3-IS median (range) P
Use of antibiotics
Gut decontamination: rifaximin vs
Cipro/Metro (74/56)
12.9 (0.0-101.9) vs 5.3 (0.0-40.2) .008
Systemic antibiotics in case of
neutropenic infections before
ASCT (55/71): without or with
13.7 (0.0-63.6) vs 0.3 (0.0-101.9) ,.0001
Conditioning: RIC vs standard
(112/19)
8.4 (0.0-101.9) vs 2.4 (0.0-29.6) NS
NOD2/CARD15 genotype: wild
type (104)/risk allele (26)
9.2 (0.0-101.9) vs 0.6 (0.0-20.9) .002
Stage of underlying disease: early
or intermediate (85)/late (45)
6.6 (0-63.6) vs 6.9 (0-101.9) NS
Patient age #50 y (49)/.50 y (81) 4.5 (0-59.4) vs 11.9 (0-101.9) NS
Significant differences in urinary 3-IS levels were observed depending on the
antibiotics administered for gut decontamination, the use of systemic antibiotics prior
to ASCT, and NOD2/CARD15 genotype, respectively. Parentheses indicate number
of valid cases; in 4 cases, no data for systemic antibiotic therapy prior to ASCT were
available. Significance level ,.05.
Cipro/Metro, ciprofloxacin and metronidazole; NS, not significant; RIC, reduced
intensity conditioning.
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These observations suggest mechanisms for how microbiota
might contribute to protection from intestinal inﬂammation and
possibly GVHD. First, indole and its metabolites may be directly
involved. So far, 3-IS has been known as a mediator of endothelial
damage and cardiovascular disease in patients suffering from renal
failure.15 However, our results appear to support laboratory ﬁnd-
ings that microbiota-derived indole and derivatives thereof, such as
indole-3-aldehyde and 5-hydroxyindole, do not only support sur-
vival of mixed microbial communities16,17 but also exert bacterio-
static effects on gram-negative enteric bacilli and certain cocci,18,19
provide colonization resistance to Candida albicans,17 and strengthen
epithelial cell barrier properties and protection from inﬂammation
by simultaneously decreasing and increasing expression of proin-
ﬂammatory and anti-inﬂammatory cytokines, respectively.17,20 In
addition, 3-IS was described to directly regulate T-cell differenti-
ation by stimulating Th2 responses, which may also contribute to
GVHD protection.21
Second, the association of Lachnospiraceae with high 3-IS-levels
is of major interest. This does not imply that the identiﬁed OTUs all
produce and release indole; theymay just grow better in the presence
of indole and some of its derivatives, which have proved capable of
slowing the growth of other bacteria such as gram-negative enteric
bacilli.18,19 Conversely, the latter will grow better in the absence
of indole. Independent of the biological effects of indole within
microbial communities and on the human host, the data support the
recentﬁnding that Lachnospiraceae, and in particularmembers of the
genus Blautia, which is represented in the present data set by OTU
AY990000 (supplemental Table 1), protect against GI GVHD.8,22
Closely related is the genus Roseburia, which has been associated
with the generation of the short-chain fatty acid butyrate,23 which
is an inducer of intestinal regulatory T cells.3,24 Thus, early loss of
bacteria of these generamay result inmassive disruption of intestinal
immunoregulation25 and contribute to development of GVHD and
associated complications. Interestingly, it is hypothesized that dis-
ruption of themicrobiome by the use of antibiotics in the ﬁrst months
after birth may be responsible for the development of autoimmune
disorders in children as microbiota shifts occur in a sensitive period
of immune reconstitution.26-28 As the early period after ASCT
also represents a period of immune reconstitution, this vulnerability
might explain why microbiota changes immediately after ASCT
trigger long-term complications. Further studies are needed to
address this potential link.
Not unexpectedly, urinary 3-IS levels early after transplantation
were inﬂuenced by the use of antibiotics for prophylaxis and treatment
of neutropenic infections. This effect was more pronounced when
broad-spectrum antibiotics were started prior to ASCT.Metronidazole,
which has been used for gut decontamination, and both piperacillin/
tazobactam and meropenem, which are the preferred antibiotics used
for treatment of neutropenic infection, suppress Clostridiales and, thus,
may contribute to low urinary 3-IS levels.
Finally, we have found a highly interesting and as yet not described
association between urinary 3-IS levels and NOD2/CARD15 variants,
which may explain partially our previously described association of
NOD2/CARD15 variants with poor outcome following ASCT and
discussed effects of decontamination.29 NOD2/CARD15 has been
shown to regulate production of antimicrobial peptides both in Paneth
cells30 and in neutrophils. Therefore,NOD2/CARD15 deﬁciencymight
trigger microbiota shifts resulting in increased inﬂammatory activities
as already demonstrated in inﬂammatory bowel disease.31 Most of
these shifts again occur among Clostridiales. Further, we and others
have reported increased bacterial translocation in inﬂammatory bowel
disease patients with NOD2/CARD15 deﬁciency.32,33 Thus, the effect
ofNOD2/CARD15 deﬁciency on 3-IS levels might bemore indirect by
favoring bacterial translocation resulting in fever and early systemic
antibiotic treatment. The use of systemic antibiotics then in turn
aggravates the risk of intestinalmicrobial disruption.More detailed and
sequential 16S rRNA sequencing studies as well as experimental
approaches are needed to describe the exact interaction of NOD2/
CARD15 and urinary 3-IS levels.
Our study has several implications for clinical management of
patients, if the results are conﬁrmed in independent prospective
validation trials. First, monitoring of urinary levels of 3-IS and other
bacterial metabolites may be a more feasible approach to monitor
microbiome changes in the clinical setting. Second, lossofClostridiales
associated with production of indole or dependent on 3-IS for growth
may be directly involved in regulation of intestinal inﬂammation in the
setting of ASCT. This is also suggested by the recent observation of
Shono et al34 in mice, in which antibiotics destroying Clostridiales
increased GVHD-related pathology and mortality, whereas introduc-
tion of Clostridiales improved survival.8 Thus, careful selection of
strategies of decontamination and antibiotic treatment in combination
with pre-, pro-, and postbiotics may contribute to improved microbiota
diversity and possibly affect outcome. Finally, intestinal immune re-
constitution might have a much broader impact on development of at
least peripheral tolerance after ASCT and, therefore, should be in the
focus of future research.
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